GREGORY JULIA P
GREGORY JULIA P's purchase track record
GREGORY JULIA P has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/25/2022 | BHVN | $100K | +30.0% | -6.9% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Transaction History
| NRIX | ▲ Buy | Option Exercise | 10,750 | $20K | 9/17/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 9,523 | $100K | 10/25/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,119 | $20K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 5,998 | $21K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 9,000 | $28K | 10/3/2022 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 11,975 | $90K | 10/3/2022 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 9,000 | $21K | 10/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Nurix Advances Bexobrutideg Studies and Secures $10M Gilead Extension
Nurix has enrolled its first patient in a Phase 1b/2 study of Bexobrutideg for chronic lymphocytic leukemia, and a second enrollment began for a Bexobrutideg plus Venetoclax combination under a Roche partnership. The company also received a second research term extension for its oncology program with Gilead Sciences and secured $10 million from Gilead as part of the extended drug‑discovery collaboration. These developments show ongoing progress in Nurix’s pipeline and continued partnership support.
Nurix Advances Bexobrutideg Studies and Secures $10M Gilead Extension. Nurix has enrolled its first patient in a Phase 1b/2 study of Bexobrutideg for chronic lymphocytic leukemia, and a second enrollment began for a Bexobrutideg plus Venetoclax combination under a Roche partnership. The company also received a second research term extension for its oncology program with Gilead Sciences and secured $10 million from Gilead as part of the extended drug‑discovery collaboration. These developments show ongoing progress in Nurix’s pipeline and continued partnership support.